<DOC>
	<DOCNO>NCT02666209</DOCNO>
	<brief_summary>Participant diagnose Relapsed/ Refractory Multiple Myeloma currently participate clinical trial closing . This research study study Ulocuplumab possible treatment . It 's expanded access NCT01359657</brief_summary>
	<brief_title>Early Patient Access Single Named Patient Program Use Ulocuplumab Treatment Multiple Myeloma</brief_title>
	<detailed_description>This research study Expanded Access Trial , way provide investigational therapy individual eligible receive therapy clinical trial , serious life-threatening illness treatment available . The purpose expand access program treat participant diagnose relapsed refractory multiple myeloma investigational drug call ulocuplumab . Participants enrol program receive ulocuplumab lenalidomide dexamethasone ulocuplumab bortezomib dexamethasone . Ulocuplumab suppose kill myeloma cell . Lenalidomide , also know Revlimid® Bortezomib , also know Velcade® , approve FDA treatment Multiple Myeloma . Dexamethasone , also know Decadron® , also approve FDA treatment . It type steroid medication fight inflammation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed informed consent document Must currently participate protocol 11240 ( DFCI ) / CA 212002 ( BMS ) , tolerate therapy , still receive benefit treatment . Prior exposure Ulocuplumab DFCI Protocol 11240 ( BMS protocol CA212002 ) CXCR4 inhibitor ( small molecule within 14 day ; antibody CXCR4 within 10 week ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>